Beschreibung
Carbamazepine substantially reduces duloxetine plasma levels through CYP1A2 and CYP3A4 induction, risking loss of antidepressant efficacy.
Mechanismus
Carbamazepine induces CYP1A2 and CYP3A4, the primary enzymes responsible for duloxetine oxidative metabolism, significantly increasing its clearance.
Klinische Bedeutung
Duloxetine concentrations may drop well below effective levels; depression or pain relapse is a realistic clinical outcome.
Maßnahmen
Closely monitor clinical response; consider antidepressants less susceptible to enzyme induction (e.g., venlafaxine) if carbamazepine is required.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.